Camurus AB
CAMX
Rangering i aksjer
#4014
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Aksjekurs
$67.58
Markedsverdi
$4.02B
Endring (1 dag)
0.00%
Endring (1 år)
-2.99%
Land
SE
Handel Camurus AB (CAMX)
Kategori
Healthcare
Driftsmargin for Camurus AB (CAMX)
Driftsmargin per October 2026 TTM: 36.33%
Ifølge Camurus AB sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 36.33%. Ved slutten av 2024 hadde selskapet en driftsmargin på 25.12%.
Historikk for driftsmargin for Camurus AB fra 2011 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 36.33% | -6.92% |
| 2025 | 39.03% | 55.37% |
| 2024 | 25.12% | -18.99% |
| 2023 | 31.01% | 312.37% |
| 2022 | 7.52% | -140.19% |
| 2021 | -18.71% | -69.57% |
| 2020 | -61.48% | -81.97% |
| 2019 | -340.98% | -41.45% |
| 2018 | -582.34% | 29.87% |
| 2017 | -448.41% | 397.79% |
| 2016 | -90.08% | -31.68% |
| 2015 | -131.85% | -540.53% |
| 2014 | 29.93% | -53.52% |
| 2013 | 64.39% | 226.69% |
| 2012 | 19.71% | 0.00% |
| 2011 | 0.00% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -98.94% |
US
|
|
| -149.01% | -104.10% |
US
|
|
| 25.57% | -99.30% |
AU
|
|
| 28.81% | -99.21% |
NL
|
|
| 31.23% | -99.14% |
BE
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.